What Egret Therapeutics does

Egret Therapeutics is a clinical-stage biotherapeutics company founded in 2019 and headquartered in New York. The company is developing a proprietary PD-L1-hyFc fusion protein platform designed to modulate innate immunity, with its lead clinical asset EGT-101 (also referenced as GX-P1) being investigated for malignant cerebral edema following large vessel occlusion stroke. The platform architecture centers on engineering a PD-L1 extracellular domain fused to a hybrid Fc region to engage innate immune pathways with the aim of dampening hyperinflammatory injury in serious acute indications. Egret has completed a Phase 1a clinical trial of EGT-101 with no dose-limiting toxicities reported and is preparing for Phase 1b/2a studies. The company cites a market opportunity of $45 billion or more, anchored on the unmet need in large vessel occlusion stroke and adjacent indications where current therapeutic options are limited.

The company operates with 1–10 employees and is privately held, currently pre-revenue, with no commercial product, licensing revenue, or partnerships generating revenue disclosed. Its business model is a standard clinical-stage pharmaceutical model: revenue mechanics are contingent on eventual regulatory approval and commercialization of EGT-101 (and potential pipeline assets), with monetization expected through direct sales, out-licensing, partnership, or acquisition. Customer segments are not yet formed; post-approval, the addressable customer base would consist of hospital systems, neurology and stroke specialists, and third-party payers in major pharmaceutical markets.

Egret Therapeutics is led by CEO Daniel Chai alongside co-founders Chris Jackson (Chief Medical Officer) and Michael Lim, with additional executives Priya Jambhekar (Chief Regulatory Officer), Xiaobu Ye (Chief Clinical Development Officer), Henry Park (Chief Financial Officer), and Vedik Navale (Chief of Staff). The company completed a Pre-A financing round in February 2022 led by FAScinate Therapeutics with participation from Turret Capital Management, and in March 2026 signed a memorandum of understanding with Genexine to acquire full ownership of EGT-101/GX-P1, a transaction that, if closed, would consolidate global rights to the lead asset.

Name

Egret Therapeutics

Legal name

Egret Therapeutics

Website

https://egrettherapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Egret Therapeutics is a clinical-stage biotherapeutics company developing a proprietary PD-L1-hyFc fusion protein platform to modulate innate immunity, with lead asset EGT-101 (GX-P1) for malignant cerebral edema after large vessel occlusion stroke.

Ownership category

akta.pro rank

Product category

Clinical-stage Biotherapeutics

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• Clinical-stage biotherapeutics
• Neuroprotective biologics
• Fusion protein platform
• Stroke treatment drug
• Innate immunity modulation

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue biotech company developing EGT-101/GX-P1 for clinical use. Expected to generate revenue through pharmaceutical product sales upon regulatory approval.

Core offering

Egret Therapeutics is a clinical-stage biotherapeutics company developing EGT-101 (also known as GX-P1), a first-in-class PD-L1-hyFc fusion protein targeting innate immunity modulation. The lead asset is being developed for malignant cerebral edema following large vessel occlusion stroke and Delayed Cerebral Ischemia (DCI), with Phase 1a trials completed showing no dose-limiting toxicities and Phase 1b/2a trials in preparation.

Product overview

Egret Therapeutics is a biopharmaceutical company developing a single lead asset, EGT-101 (GX-P1), a PD-L1-hyFc fusion protein. The company is transitioning from an exclusive global licensee to outright owner of this asset following a March 2026 Memorandum of Understanding with Genexine, Inc. The product is in clinical development targeting a potentially $45 billion-plus global market opportunity for acute ischemic injury treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• EGT-101 (GX-P1)

Quantifiable outcome

• Phase 1a trials completed with no dose-limiting toxicities demonstrated favorable safety profile

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Genexine, Inc.coreStrategic or Co-development Partner · 6 March 2026Signed non-binding Memorandum of Understanding on March 6, 2026 for Egret to acquire full ownership of lead asset GX-P1 (EGT-101) and all related intellectual property. This strategic transaction would transition Egret from an exclusive global licensee to outright owner of the asset, providing complete control over the technology and its commercialization.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• NoNO Inc. Privately-held biotech focused on neuroprotection in stroke and CNS injuries (e.g., PSD-95 inhibitor NA-1); closely comparable in addressing acute ischemic injury where limited neuroprotective options exist.
• ZZ Biotech: Clinical-stage biotech developing biologic therapies (e.g., 3K3A-APC) for stroke and neurological injury; directly comparable in pursuing protein-based neuroprotection for acute ischemic stroke.
• Annexon, Inc. Clinical-stage complement-mediated neuroinflammation company; comparable in mechanism-driven CNS biologic development for neuroinflammatory conditions and addressing unmet needs in neurobiology.
• Athersys, Inc. Clinical-stage biotech developing cell therapy (MultiStem) for ischemic stroke — directly comparable in targeting large vessel occlusion stroke recovery, though using a regenerative approach rather than innate-immunity modulation.
• ReNeuron Group plc: UK-based cell therapy developer with stroke disability program (CTX); comparable in pursuing novel biologic/cell approaches to post-stroke functional recovery for a similar unmet indication.
• True Binding, Inc. Clinical-stage immunobiology company developing Fc-based biologics; comparable in using Fc-engineering and immuno-modulation to address CNS-related conditions.

Broad incumbents

• AbbVie Inc. Large pharma with significant neurology and immunology franchise (via Allergan acquisition); relevant incumbent with capability to in-license or acquire late-clinical CNS assets like EGT-101.
• Genentech / Roche: Major neuroscience player (Evrysdi, Ocrevus) with historical stroke neuroprotection programs; comparable as broad incumbent in CNS biologics with deep development and commercialization capability.
• Biogen Inc. Large neuroscience-focused biotech with broad CNS pipeline including stroke and neuroinflammation programs; relevant as a potential acquirer/partner and as a benchmark for CNS biologic commercialization.

Direct peers

• Genexine, Inc. Korean biotech that is the originator and current licensor of the EGT-101/GX-P1 PD-L1-hyFc fusion protein. Direct technology counterparty and platform peer using hyFc Fc-engineering for biologic therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egret Therapeutics